Diaziquone

TargetMol
Product Code: TAR-T61383
Supplier: TargetMol
CodeSizePrice
TAR-T61383-1mg1mg£222.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61383-5mg5mg£448.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61383-10mg10mg£624.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61383-25mg25mg£938.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61383-50mg50mg£1,243.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61383-100mg100mg£1,645.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T61383-500mg500mg£3,227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
Diaziquone is a water-soluble synthetic azacyclic benzoquinone that enhances penetration of the blood-brain barrier, has antitumor activity, and is used in the treatment of extreme renal failure.
CAS:
57998-68-2
Molecular Weight:
364.35
Purity:
0.9837
SMILES:
O=C(OCC)NC=1C(=O)C(=C(NC(=O)OCC)C(=O)C1N2CC2)N3CC3

References

Gutierrez PL, et al. Free radicals in quinone containing antitumor agents. The nature of the diaziquone (3,6,-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone) free radical. Biochim Biophys Acta. 1983;758(1):37-41. White L. Responsiveness of retinoblastoma to local diaziquone. Studies in a xenograft model. Invest Ophthalmol Vis Sci. 1990;31(5):787-791. Lee EJ, et al. Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia. Blood. 1986;67(1):182-187. Schold SC Jr, et al. Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. Cancer Res. 1984;44(6):2352-2357. Moore DJ, et al. Topical chemotherapy of intradermal Walker 256 carcinosarcoma with diaziquone and doxorubicin in the rat. Cancer Res. 1985;45(11 Pt 1):5466-5472. Kushner BH, et al. Myeloablation with diaziquone: in vitro assessment. Blood. 1987;69(6):1747-1752.